



FIG. 1


第 1 図




第 2 図 FIG. 2




第 3 図 FIG. 3




第 4 図 FIG. 4




## 第 5 図 FIG. 5



## 第 6 図 FIG. 6




第 7 図 FIG. 7



第 8 図  
FIG. 8

Recovering of cells (0.2%)  
area 1, followed by culturing



Reactivity of anti-CD97 antibody

#10.9  
第 9 図

10/009723





FIG. 11

第 11 図




FIG. 12




Fig. D

第 13 图




FIG. 14






FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 2/





FIG. 22



LANE 1: MOLECULAR WEIGHT MARKER, LOW MOLECULES  
 2: KM2532 (REDUCING CONDITIONS)  
 3: KM2550 (REDUCING CONDITIONS)  
 4: MOLECULAR WEIGHT MARKER, HIGH MOLECULES  
 5: KM2532 (NON-REDUCING CONDITIONS)  
 6: KM2550 (NON-REDUCING CONDITIONS)



FIG. 23




FIG.




FIG. 24




FIG.




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30






FIG. 31







FIG. 32





27/40  
FIG. 33




FIG. 35




FIG. 36




FIG. 37




FIG. 38






FIG. 39




FIG. 40




FIG. 41




FIG. 42






FIG. 83



NON-REDUCING CONDITIONS										REDUCING CONDITIONS										
LANE	1: MOLECULAR WEIGHT MARKER, HIGH MOLECULES	2: KM8969	3: KM2550, CHIMERIC ANTIBODY	4: KM8550, HV0LV0 (I)	5: KM8551, HV0LV0 (IV)	6: KM8552, HV3LV0 (I)	7: KM8553, HV3LV0 (IV)	8: KM8554, HV0LV4	9: KM8555, HV3LV4	LANE	10: MOLECULAR WEIGHT MARKER, HIGH MOLECULES	11: KM8969	12: KM2550, CHIMERIC ANTIBODY	13: KM8550, HV0LV0 (I)	14: KM8551, HV0LV0 (IV)	15: KM8552, HV3LV0 (I)	16: KM8553, HV3LV0 (IV)	17: KM8554, HV0LV4	18: KM8555, HV3LV4	19: MOLECULAR WEIGHT MARKER, LOW MOLECULES

FIG. 44






FIG. 45

FIG. 46




FIG. 47

H CHAIN		FR1	CDR1	FR2	CDR2	
1750 MOUSE	1	QAFLOQSGAELVRPGASVKMSCKASGYTFI	NYNMH	WVKQTPRQGLEWIG	AIFPGNGFTSY	60
1750 HVO	1	QVQLVQSGAEVKKPGASVKVSCCKASGYTFI	NYNMH	WVRQAPGQGLEWMG	AIFPGNGFTSY	60
1750 HV3	1	QVQLVQSGAEVKKPGASVKVSCCKASGYTFI	NYNMH	WVRQAPGQGLEWMG	AIFPGNGFTSY	60
		FR3		CDR3	FR4	
61	NQKFKG	KATLTVDKSSSTVYMQRLSLTSEDSAVYFCAR		DGDYFDY	WGQGTTLTVSS	117
61	NQKFKG	RVTITVDKSTSTAYMELSSLRSEDYAVYFCAR		DGDYFDY	WGQGTTLTVSS	117
61	NQKFKG	RVTITVDKSTSTAYMQLRSLRSEDYAVYFCAR		DGDYFDY	WGQGTTLTVSS	117
		8284	95			

FIG. 48

L CHAIN									
		FR1	CDR1	FR2	CDR2	FR3			
1750	MOUSE	1	QIVLTQSPA IMSASLGEEITLTC	SASSSVSYMH	WYQQKSGTSPKLLIY	RTSNLAS	GVPR	60	
1750	LV0 (I)	1	DIQMTQSPSSLASVGDRTITC	SASSSVSYMH	WYQQKPGTAPKLLIY	RTSNLAS	GVPSR	60	
1750	LV4	1	DIQMTQSPSSLASVGEVITTC	SASSSVSYMH	WYQQKPGTAPKLLIY	RTSNLAS	GVPSR	60	
1718									
6970									
			CDR3	FR4					
61		FSGSGSGTFYSLTISSEAEADAAYC	HQWSMYT	FGGGTKLEIKR	105				
61		FSGSGSGTDFLTITISLQPEDFATYIC	HQWSMYT	FGGGTKVEIKR	105				
61		FSGSGSGTFYTLTISLQPEDFATYIC	HQWSMYT	FGGGTKVEIKR	105				
6970									
			CDR1	FR2	CDR2	FR3			
1750	MOUSE	1	QIVLTQSPA IMSASLGEEITLTC	SASSSVSYMH	WYQQKSGTSPKLLIY	RTSNLAS	GVPR	60	
1750	LV0 (IV)	1	DIVMTQSPDSLAVSLGERATINC	SASSSVSYMH	WYQQKPGQPPKLLIY	RTSNLAS	GVPR	60	
6970									
			CDR3	FR4					
61		FSGSGSGTFYSLTISSEAEADAAYC	HQWSMYT	FGGGTKLEIKR	105				
61		FSGSGSGTDFLTITISLQAEADVAVYIC	HQWSMYT	FGGGTKVEIKR	105				